Clinical Trial Update: Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

View source ↗

Summary

Regulatory approval has been granted for abiraterone acetate (Zytiga) for advanced prostate cancer, indicating marketing authorization for this indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Zytiga (abiraterone acetate)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Prostate Neoplasms, Genital Neoplasms, Male | Status: APPROVED_FOR_MARKETING